Clinic of Pediatric Respiratory Diseases and Tuberculosis in National Institute of Pediatric Tuberculosis and Respiratory Diseases in Dolny Smokovec, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Slovak Republic.
Physiol Res. 2020 Mar 27;69(Suppl 1):S29-S34. doi: 10.33549/physiolres.934398.
Asthma is a complex disease with a variable course. Efforts to identify biomarkers to predict asthma severity, the course of disease and response to treatment have not been very successful so far. Biomarker research has expanded greatly with the advancement of molecular research techniques. An ideal biomarker should be suitable to identify the disease as well the specific endotype/phenotype, useful in the monitoring of the disease and to determine the prognosis, easily to obtain with minimum discomfort or risk to the patient. An ideal biomarker should be suitable to identify the disease as well the specific endotype/phenotype, useful in the monitoring of the disease and to determine the prognosis, easily to obtain with minimum discomfort or risk to the patient - exhaled breath analysis, blood cells and serum biomarkers, sputum cells and mediators and urine metabolites could be potential biomarkers of asthma bronchiale. Unfortunately, at the moment, an ideal biomarker doesn't exist and the overlap between the biomarkers is a reality. Using panels of biomarkers could improve probably the identification of asthma endotypes in the era of precision medicine.
哮喘是一种具有多变病程的复杂疾病。迄今为止,人们努力寻找生物标志物来预测哮喘的严重程度、疾病进程和治疗反应,但并未取得很大成功。随着分子研究技术的进步,生物标志物研究已经大大扩展。理想的生物标志物应该能够识别疾病以及特定的表型/表型,有助于监测疾病并确定预后,并且易于获取,对患者的不适或风险最小。理想的生物标志物应该能够识别疾病以及特定的表型/表型,有助于监测疾病并确定预后,并且易于获取,对患者的不适或风险最小-呼气分析、血液细胞和血清生物标志物、痰细胞和介质以及尿液代谢物可能是支气管哮喘的潜在生物标志物。不幸的是,目前,还没有理想的生物标志物,而且生物标志物之间存在重叠是一个现实。使用生物标志物组可能会改善精准医学时代哮喘表型的识别。